Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017.
The European patent EP2539366 covers the monoclonal antibody candidate BAN0805 per se, intended for treatment of neurodegenerative disorders, including Parkinson’s disease. Validated national patents will expire on February 25, 2031 and patent term extensions will be available for up to five years after marketing authorizations have been approved. Corresponding patents are also granted in major markets including US, Japan and China.
For more information, please contact:
Dr. Gunilla Osswald, CEO
Phone: + 46 (0)8 695 69 30
E-mail: gunilla.osswald@bioarctic.se
Christina Astrén, Head IR & Communications
Phone: + 46 (0)70 835 43 36
E-mail: christina.astren@bioarctic.se
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on October 13, 2017, at 10.15 a.m. CET.
About BAN0805
BioArctic’s product candidate BAN0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. BAN0805 aims to halt or slow down the progression of the disease in Parkinson patients. In preclinical studies, BAN0805 has been shown to decrease the levels of alpha-synuclein protofibrils, decrease motor symptoms and double the life span of transgenic Parkinson mice.1)
The treatments for Parkinson’s disease that are currently on the market are focused on relieving the motor symptoms in Parkinson’s patients. BAN0805 has the potential to become one of the first disease modifying treatments for Parkinson’s disease.
About BioArctic
BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (STO:BIOA B). www.bioarctic.com
1)Ingelsson M, 2016. ‘Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other Lewy body disorders’, Front Neurosci, 10: 408